Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modern Chinese Medicine Group Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$-0.03.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.02.
During the past 12 months, the average EBIT per Share Growth Rate of Modern Chinese Medicine Group Co was -162.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Modern Chinese Medicine Group Co's EBIT per Share or its related term are showing as below:
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Modern Chinese Medicine Group Co was 36.50% per year. The lowest was -43.10% per year. And the median was 24.20% per year.
HKSE:01643's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Modern Chinese Medicine Group Co (HKSE:01643) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Modern Chinese Medicine Group Co EBIT per Share Related Terms
Modern Chinese Medicine Group Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modern Chinese Medicine Group Co (HKSE:01643) has a EBIT per Share of HK$-0.02 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Modern Chinese Medicine Group Co and its competitors. According to the industry distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 812 companies in the Drug Manufacturers industry.
Is Modern Chinese Medicine Group Co's EBIT per Share too high?
Modern Chinese Medicine Group Co's current EBIT per Share is HK$-0.02. Based on the distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Modern Chinese Medicine Group Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Modern Chinese Medicine Group Co's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Modern Chinese Medicine Group Co ranks #999999 out of 812 companies for EBIT per Share. This places Modern Chinese Medicine Group Co in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Modern Chinese Medicine Group Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modern Chinese Medicine Group Co's current EBIT per Share is HK$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modern Chinese Medicine Group Co stock overvalued right now?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co (HKSE:01643) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.85 — trading 463.3% above its estimated fair value. The current EBIT per Share is HK$-0.02. Modern Chinese Medicine Group Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Modern Chinese Medicine Group Co (HKSE:01643), the current EBIT per Share is HK$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Modern Chinese Medicine Group Co (HKSE:01643) Overvalued in 2026?
Based on GuruFocus' analysis, Modern Chinese Medicine Group Co stock appears to be overvalued.
The current stock price of HK$0.85 is trading 463.3% above its estimated GF Value™ of HK$0.15.
GuruFocus considers Modern Chinese Medicine Group Co to be Significantly Overvalued.
Key valuation signals for HKSE:01643:
EBIT per Share: HK$-0.02
GF Value™: HK$0.15 vs. price of HK$0.85 (463.3% above fair value)
No single metric tells the full story. See the HKSE:01643 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Modern Chinese Medicine Group Co Ltd is engaged in the production of Proprietary Chinese Medicines. It offers both OTC and prescribed medicines intended for use by the Middle-aged and the Elderly in the PRC. Its products include liver protection tablets, Shanmei capsules, Qi and blood supplement pills, and Xiaohuoluo pills, among others. Geographically, the company derives its key revenue from the People's Republic of China.
53GF Score
Get the complete analysis for HKSE:01643
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01643 has been successfully added to your 
